HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

NSF gives Red Bull wings?

This article was originally published in The Tan Sheet

Executive Summary

Red Bull Energy Drink is the first product to be certified under NSF International's new Athletic Banned Substances Certification Program, the third-party certification firm announces April 13. The certification allows cans of Red Bull to bear the NSF Certified for Sport mark in the future. According to NSF, four other companies are currently in the certification process, and more products are expected to be added to the online 1list by May. The products under review include multi-vitamins, protein drinks and post-workout recovery supplements, according to the firm. NSF describes the program as a filling a "unique need" for players, industry and possibly government; Major League Baseball and the MLB Players association endorsed the program in March (2"The Tan Sheet" April 10, 2006, p. 5)...

You may also be interested in...



Supplement Industry Challenges Include Shrinking Claims World – Israelsen

The trend toward a more expansive definition of disease in pharmaceutical advertising could hinder the dietary supplement industry's ability to communicate product benefit, according to consultant and UNPA director Loren Israelsen

US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising

US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”

Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa

The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

RS125518

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel